title: Cell-based antiviral assays for screening and profiling inhibitors against dengue virus.
abstract: Dengue, a mosquito-borne virus of the Flaviviridae family, is reemerging as one of the most important human pathogens in tropical and subtropical regions of the world. It is estimated that 2.5 billion people live in areas at risk for transmission of dengue virus (DENV). Furthermore, it causes significant morbidity and mortality with 50-100 million infections per year. Currently, there are no vaccines commercially available and no effective antiviral drugs for treatment of DENV infections. In this chapter, we describe a plaque reduction assay and a cell-based high-throughput antiviral assay for identifying inhibitors against DENV. The latter is a homogeneous high-throughput assay that has been fully validated according to the Food and Drug Administration (FDA) guidelines for assay validation and can be used for screening compound libraries.
authors.affiliation: Janssen Infectious Diseases-Diagnostics BVBA, Johnson & Johnson Corporation, Beerse, Belgium.
authors.forename: Edwin Yunhao
authors.initials: EY
authors.lastname: Gong
authors.forename: Marleen
authors.initials: M
authors.lastname: Clynhens
authors.forename: Tania
authors.initials: T
authors.lastname: Ivens
authors.forename: Pedro
authors.initials: P
authors.lastname: Lory
authors.forename: Kenny
authors.initials: K
authors.lastname: Simmen
authors.forename: Guenter
authors.initials: G
authors.lastname: Kraus
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000633:toxicity; D018929:Cell Culture Techniques; D002460:Cell Line; D002522:Chlorocebus aethiops; D006224:Cricetinae; D003716:Dengue Virus / Q000187:drug effects*; D057166:High-Throughput Screening Assays; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods*; D014709:Vero Cells
chemical_list: D000998:Antiviral Agents